Cargando…
EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
KRAS is one of the most important proto-oncogenes. Its mutations occur in almost all tumor types, and KRAS mutant cancer is still lack of effective therapy. Prenyl-binding protein phosphodiesterase-δ (PDEδ) is required for the plasma membrane association and subsequent activation of KRAS oncogenic s...
Autores principales: | Chen, Yue-hong, Lv, Hao, Shen, Ning, Wang, Xiao-min, Tang, Shuai, Xiong, Bing, Ding, Jian, Geng, Mei-yu, Huang, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471410/ https://www.ncbi.nlm.nih.gov/pubmed/31316177 http://dx.doi.org/10.1038/s41401-019-0268-y |
Ejemplares similares
-
Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
por: Lee, Jungeun, et al.
Publicado: (2022) -
PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas
por: Klein, Christian H., et al.
Publicado: (2018) -
Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016) -
Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models
por: Chen, Long, et al.
Publicado: (2022) -
KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer
por: Casique-Aguirre, Diana, et al.
Publicado: (2018)